0001127602-19-025555.txt : 20190731 0001127602-19-025555.hdr.sgml : 20190731 20190731175603 ACCESSION NUMBER: 0001127602-19-025555 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190729 FILED AS OF DATE: 20190731 DATE AS OF CHANGE: 20190731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kuntz Richard CENTRAL INDEX KEY: 0001341125 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36820 FILM NUMBER: 19990089 MAIL ADDRESS: STREET 1: MEDTRONIC, INC. STREET 2: 710 MEDTRONIC PWKY MS LC 310 CITY: MINNEAPOLIS STATE: MN ZIP: 55432 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Medtronic plc CENTRAL INDEX KEY: 0001613103 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 000000000 FISCAL YEAR END: 0426 BUSINESS ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 BUSINESS PHONE: 01135314381700 MAIL ADDRESS: STREET 1: 20 ON HATCH, LOWER HATCH STREET CITY: DUBLIN STATE: L2 ZIP: 2 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Ltd DATE OF NAME CHANGE: 20150112 FORMER COMPANY: FORMER CONFORMED NAME: Medtronic Holdings Ltd DATE OF NAME CHANGE: 20140711 FORMER COMPANY: FORMER CONFORMED NAME: Kalani I Ltd DATE OF NAME CHANGE: 20140709 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2019-07-29 0001613103 Medtronic plc MDT 0001341125 Kuntz Richard 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 1 SVP & Chief Medical & Science Ordinary Shares 2019-07-29 4 A 0 10330 0 A 110755 D Stock Option (Right to Buy) 103.26 2019-07-29 4 A 0 68901 0 A 2020-07-29 2029-07-29 Ordinary Shares 68901 68901 D Stock Option (Right to Buy) 103.26 2019-07-29 4 A 0 1615 0 A 2020-07-29 2029-07-29 Ordinary Shares 1615 1615 D The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth during the 36-month period ending on the last day of the Company's fiscal year 2022 equals or exceeds a 3% cumulative compound annual growth rate, as determined by the Compensation Committee. This balance increased by 298 shares due to exempt transactions such as dividend reinvestment. These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. /s/ Perry F. Sekus, attorney-in-fact 2019-07-31